Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, MyelomaJanuary 30, 2021
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, MyelomaAugust 30, 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosisJune 23, 2021
European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020
